FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Author:
Affiliation:
1. Leiden University Medical Center, Leiden, the Netherlands.
2. Checkmate Pharmaceuticals, Cambridge, Massachusetts.
Publisher
Mary Ann Liebert Inc
Subject
Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry
Link
http://www.liebertpub.com/doi/pdf/10.1089/nat.2016.0657
Reference4 articles.
1. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
2. Eteplirsen for the treatment of Duchenne muscular dystrophy
3. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
4. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
Cited by 297 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Breaking barriers: Innovative approaches for skin delivery of RNA therapeutics;International Journal of Pharmaceutics;2024-08
2. Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions;Frontiers in Molecular Neuroscience;2024-07-24
3. Cardiomyopathies Caused by Pathogenic Variants in the DMD Gene;Kardiologiia;2024-06-30
4. Intracoronary Administration of Epinephrine in the Refractory No-Reflow Phenomenon in Patients With Acute Myocardial Infarction;Kardiologiia;2024-06-30
5. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs;BioDrugs;2024-06-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3